Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Insight Partners | PRODUCT CODE: 1764946

Cover Image

PUBLISHER: The Insight Partners | PRODUCT CODE: 1764946

Europe Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing

PUBLISHED:
PAGES: 162 Pages
DELIVERY TIME: 1-5 business days
SELECT AN OPTION
PDF (Single User License)
USD 3450
PDF (Site License)
USD 4450
PDF (Enterprise License)
USD 5450

Add to Cart

The Europe biologics market was valued at US$ 1,15,057.6 million in 2023 and is expected to reach US$ 4,15,468.4 million by 2031; it is estimated to register a CAGR of 17.4% from 2023 to 2031.

Preference for Outsourcing Manufacturing Operations Drives Europe Biologics Market

Biologics manufacturing is a complex process whose success depends on the proper execution and monitoring of all operations. The manufacturing facilities need trained personnel with technical knowledge of bioprocessing and process engineering. Managing the attempts to reach the first clinical trial using a manual and open manufacturing method and then building a more commercially suitable process can be tricky for an experienced team. Thus, manufacturers choose to work with contract development and manufacturing organizations (CDMOs) to accelerate their clinical studies and commercialization operations. CDMOs provide product development, clinical trial support, manufacturing, and commercialization services to biologics companies on a contract basis. Partnering with CDMO enables scalability and access to technical expertise without overhead costs, along with higher speed to market and greater cost efficiencies for biologics manufacturers. In April 2022, ThermoGenesis established its own CDMO facility in California, US, to provide CDMO services to cell and gene therapy manufacturers. Using its expertise, the company focuses on manufacturing chimeric antigen receptor-T cell (CAR-T cell), T-cell receptor (TCR), tumor-infiltrating leukocyte (TIL), natural killer cell (NK), iPSC, and mesenchymal stem cell (MSC). Outsourcing biologics manufacturing to CDMOs proves cost-effective for manufacturers. Additionally, they gain access to the technologically advanced infrastructure and expertise of CDMOs. CDMOs employ proper, mapped processes for manufacturing biologics. Thus, the surging preference for outsourcing biologics manufacturing operations to CDMOs fuels the biologics market growth.

Europe Biologics Market Overview

The biologics market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe holds the second-largest market share, which can be attributed to the increasing cancer burden and technological advancements in cancer diagnostics to aid in early detection. The growing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is also contributing to the biologics market progress in Europe. Germany invests significantly in healthcare research and infrastructure among all countries in the European Union (EU). According to Eurostat, the healthcare expenditure in Germany accounted for US$ 394.9 million in 2015, which was one of the highest among the relative countries in the region. According to OECD Health Statistics 2015, health spending in Germany is growing faster than the actual OECD-predicted average; this can be associated with the higher capital investments made to support the development, research, and manufacturing of pharmaceuticals. Thus, the robust financial backing to the healthcare sector bolsters the biologics market in Germany.

Europe Biologics Market Revenue and Forecast to 2031 (US$ Million)

Europe Biologics Market Segmentation

The Europe biologics market is categorized into product, application, source, manufacturing, and country.

Based on product, the Europe biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.

In terms of application, the Europe biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.

By source, the Europe biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.

Based on manufacturing, the Europe biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.

In terms of country, the Europe biologics market is segmented into Germany, the UK, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe biologics market share in 2023.

AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Europe biologics market.

Product Code: BMIRE00031589

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Biologics Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic Diseases
    • 4.1.2 Preference for Outsourcing Manufacturing Operations
  • 4.2 Market Restraints
    • 4.2.1 High Cost of Biologics
  • 4.3 Market Opportunities
    • 4.3.1 Gene and Cell Therapy Advancements in Biologics
  • 4.4 Future Trends
    • 4.4.1 Strategic Initiatives by Companies
  • 4.5 Impact of Drivers and Restraints:

5. Biologics Market - Europe Analysis

  • 5.1 Europe Biologics Market Revenue (US$ Million), 2021-2031
  • 5.2 Europe Biologics Market Forecast Analysis

6. Europe Biologics Market Analysis - by Product

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Overview
    • 6.1.2 Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.2 Vaccine
    • 6.2.1 Overview
    • 6.2.2 Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.3 Recombinant Hormones/Proteins
    • 6.3.1 Overview
    • 6.3.2 Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.4 Cell and Gene Therapy
    • 6.4.1 Overview
    • 6.4.2 Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Europe Biologics Market Analysis - by Application

  • 7.1 Cancer
    • 7.1.1 Overview
    • 7.1.2 Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Infectious Diseases
    • 7.2.1 Overview
    • 7.2.2 Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Autoimmune Diseases
    • 7.3.1 Overview
    • 7.3.2 Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Biologics Market Analysis - by Source

  • 8.1 Mammalian
    • 8.1.1 Overview
    • 8.1.2 Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Microbial
    • 8.2.1 Overview
    • 8.2.2 Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Biologics Market Analysis - by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Overview
    • 9.1.2 Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 In-house
    • 9.2.1 Overview
    • 9.2.2 In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Biologics Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Europe Biologics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 Germany: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.2.1 Germany: Europe Biologics Market Share - by Product
        • 10.1.1.2.2 Germany: Europe Biologics Market Share - by Application
        • 10.1.1.2.3 Germany: Europe Biologics Market Share - by Source
        • 10.1.1.2.4 Germany: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.3 United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.3.1 United Kingdom: Europe Biologics Market Share - by Product
        • 10.1.1.3.2 United Kingdom: Europe Biologics Market Share - by Application
        • 10.1.1.3.3 United Kingdom: Europe Biologics Market Share - by Source
        • 10.1.1.3.4 United Kingdom: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.4 Italy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.4.1 Italy: Europe Biologics Market Share - by Product
        • 10.1.1.4.2 Italy: Europe Biologics Market Share - by Application
        • 10.1.1.4.3 Italy: Europe Biologics Market Share - by Source
        • 10.1.1.4.4 Italy: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.5 France: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.5.1 France: Europe Biologics Market Share - by Product
        • 10.1.1.5.2 France: Europe Biologics Market Share - by Application
        • 10.1.1.5.3 France: Europe Biologics Market Share - by Source
        • 10.1.1.5.4 France: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.6 Spain: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.6.1 Spain: Europe Biologics Market Share - by Product
        • 10.1.1.6.2 Spain: Europe Biologics Market Share - by Application
        • 10.1.1.6.3 Spain: Europe Biologics Market Share - by Source
        • 10.1.1.6.4 Spain: Europe Biologics Market Share - by Manufacturing
      • 10.1.1.7 Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 10.1.1.7.1 Rest of Europe: Europe Biologics Market Share - by Product
        • 10.1.1.7.2 Rest of Europe: Europe Biologics Market Share - by Application
        • 10.1.1.7.3 Rest of Europe: Europe Biologics Market Share - by Source
        • 10.1.1.7.4 Rest of Europe: Europe Biologics Market Share - by Manufacturing

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Market Initiative
  • 11.3 Partnerships and Collaborations
  • 11.4 Other Developments

12. Company Profiles

  • 12.1 AbbVie Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Pfizer Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Samsung Biologics Co Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 ADMA Biologics, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 WuXi Biologics Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Catalent Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AGC Biologics AS
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 AstraZeneca Plc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Amgen Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Nitto Avecia
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Quality Assistance s.a.
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments

13. Appendix

  • 13.1 About Us
Product Code: BMIRE00031589

List Of Tables

  • Table 1. Europe Biologics Market Segmentation
  • Table 2. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Product
  • Table 4. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
  • Table 5. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Source
  • Table 6. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Manufacturing
  • Table 7. Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 9. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 10. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 11. Germany: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 12. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 13. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 14. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 15. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 16. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 17. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 18. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 19. Italy: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 20. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 21. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 22. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 23. France: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 24. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 25. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 26. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing
  • Table 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
  • Table 29. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
  • Table 30. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Source
  • Table 31. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Manufacturing

List Of Figures

  • Figure 1. Europe Biologics Market Segmentation - Country
  • Figure 2. Europe Biologics Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Biologics Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Biologics Market Share (%) - by Product (2023 and 2031)
  • Figure 6. Monoclonal Antibodies: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 7. Vaccine: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Recombinant Hormones/Proteins: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Cell and Gene Therapy: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Europe Biologics Market Share (%) - by Application (2023 and 2031)
  • Figure 12. Cancer: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Infectious Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Autoimmune Diseases: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Others: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Europe Biologics Market Share (%) - by Source (2023 and 2031)
  • Figure 17. Mammalian: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 18. Microbial: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Europe Biologics Market Share (%) - by Manufacturing (2023 and 2031)
  • Figure 20. Outsourced: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. In-house: Europe Biologics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Europe Biologics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. Germany: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 24. United Kingdom: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 25. Italy: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 26. France: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 27. Spain: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 28. Rest of Europe: Europe Biologics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!